Clinerion enters Asia through strategic alliance with ASUS Life
The alliance between Clinerion and ASUS Life looks to accelerate drug development and was signed today at the HIMSS 17 conference in Orland, Florida.
ASUS Life is a joint venture that combines ASUS’ information technology with the clinical research services of the Show Chwan Healthcare System, in Taiwan.
“The new alliance expands the geographic reach of sponsors seeking cohorts relevant to their clinical trials,” Ulf Claesson, Clinerion CEO, told us.
According to the company, trial staff will be able to recruit eligible patients at Show Chwan’s eight hospital sites using Clinerion’s Patient Recruitment System (PRS).
Due to its live, EHR-based integration with partner hospitals, Clinerion’s PRS can find patients “much more rigorously than through traditional means,” explained Claesson. “This means 10 to 30 times more patients found and finding them in minutes rather than days, or weeks.”
For CROs, he said Clinerion’s PRS provides a new tool for clinical trial management, enabling them to support trial sponsors “more efficiently and effectively.”
The collaboration also enables patient matching with medications for rare and orphan diseases and real-world data generation for evidence analyses.
Patient data technology in Asia
“When it comes to patient data technology, Asia is already at a good level,” Claesson, explained. “As all over the globe quality differs from country to country and hospital to hospital, but in general the quality and consistency of digital patient data are excellent.”
Claesson said Taiwan is at the forefront – which was why he explained the partnership with ASUS was a good fit.
“What is still missing is technology that can network them to the rest of the world and make their hospitals stand out when trial siting decisions are made,” he added. “This is where Clinerion comes in.”
The company has plans to expand coverage in key geographies, such as Korea, Japan, China, and Singapore.
“Expect to hear more from Clinerion on this topic,” Claesson said.